Abevmy 100 mg/4 ml IV Infusion is a targeted cancer therapy containing bevacizumab. It is given by intravenous infusion, under specialist supervision, for several advanced cancers including colorectal, lung, kidney, brain, cervical and ovarian cancers.
There are 12 brands of Bevacizumab listed in Bangladesh. 1 of them has a lower unit price than Abevmy. The lowest listed price is Bevastim 100 mg/4 ml IV Infusion at ৳ 13925.00 per unit.
What is Abevmy 100 mg/4 ml IV Infusion?
Abevmy 100 mg/4 ml IV Infusion is a targeted cancer therapy. Its active ingredient is bevacizumab, which works by binding to a protein called VEGF and blocking its interaction with receptors on the surface of endothelial cells. This interaction normally supports the growth of new blood vessels, which tumours can use to grow and spread. By interfering with this process, bevacizumab is used as part of treatment plans for certain advanced cancers. It is given as an intravenous infusion in a clinical setting. The doctor decides the dose and course, and treatment is supervised by a cancer specialist.
Uses of Abevmy
Abevmy is used in the treatment of several advanced cancers. These include metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, persistent, recurrent or metastatic carcinoma of the cervix, and platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. It is used as part of a wider treatment plan chosen by the cancer specialist, often alongside other cancer medicines. Ask your doctor how it fits into your own treatment.
How to use Abevmy
Abevmy is given as an intravenous infusion by a healthcare professional, usually in a hospital or cancer treatment setting. It is not intended for use at home. The doctor decides the dose, the schedule and how long treatment continues, based on the type of cancer and other medicines being used. Tell the infusion team about any reactions during or after the infusion. Attend scheduled appointments and blood tests, and ask your doctor or pharmacist about anything you do not understand.
Side effects of Abevmy
Some people may experience side effects. These can include dry mouth, cough, voice changes, loss of appetite, diarrhoea, nausea, vomiting, constipation, mouth sores, headache, back pain, cold-like symptoms such as a stuffy nose, sneezing or sore throat, dry or watery eyes, dry or flaky skin, hair loss, changes in taste, jaw pain, swelling or numbness, loose teeth or gum infection. Tell your doctor or nurse about any side effect, especially if it bothers you or does not settle.
Safety and precautions
Abevmy is given under specialist supervision, and the doctor decides whether it is suitable for you. The risk of certain blood vessel problems during treatment is increased in people with a history of arterial thromboembolism, diabetes, or older age; discuss your history with your doctor. The manufacturer's labelling does not list specific contraindications, but you should still tell your doctor about all your conditions and medicines. It is pregnancy category C, and there are no adequate or well-controlled studies in pregnant women; it is not known whether it passes into human milk. Ask your doctor before use if you are pregnant, planning pregnancy or breastfeeding.
Frequently asked questions
What is the price of Abevmy 100 mg/4 ml IV Infusion?
The listed price is ৳ 14500.00.
What is Abevmy used for and what kind of medicine is it?
Abevmy is a targeted cancer therapy containing bevacizumab. It is used for certain advanced cancers, including colorectal, lung, kidney, brain, cervical and ovarian cancers, as part of a treatment plan chosen by a cancer specialist. Ask your doctor how it fits your case.
Who should avoid Abevmy or ask the doctor first?
The manufacturer's labelling does not list specific contraindications, but the doctor decides who can use it. Tell your doctor about any history of arterial thromboembolism, diabetes, older age, pregnancy, planning pregnancy or breastfeeding, and any other health conditions, so suitability can be assessed.
Which medicines may interact with Abevmy?
Studies with irinotecan given as part of the FOLFIRI regimen showed no significant effect of bevacizumab on irinotecan or its active metabolite. In a lung cancer study, exposure to carboplatin or paclitaxel given with bevacizumab was generally similar, though some patients had lower paclitaxel exposure. Tell your doctor and pharmacist about every medicine you take.
Abevmy is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of:
Metastatic colorectal cancer, with intravenous 5-fluorouracil-based chemotherapy for first-or second-line treatment.
Metastatic colorectal cancer, with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for second-line treatment in patients who have progressed on a first-line Abevmy containing regimen.
... Read more
Abevmy is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of:
Metastatic colorectal cancer, with intravenous 5-fluorouracil-based chemotherapy for first-or second-line treatment.
Metastatic colorectal cancer, with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy for second-line treatment in patients who have progressed on a first-line Abevmy containing regimen.
Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first-line treatment of unresectable, locally advanced, recurrent or metastatic disease.
Glioblastoma, as a single agent for adult patients with progressive disease following prior therapy. Effectiveness of Abevmy is based on improvement in objective response rate. No data available demonstrating improvement in disease-related symptoms or survival with Abevmy.
Metastatic renal cell carcinoma with interferon alfa.
Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.
Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that is: (1) Platinum-resistant in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan. (2) Platinum-sensitive in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Abevmy as a single agent.
Limitation of Use: Abevmy is not indicated for adjuvant treatment of colon cancer.
Pharmacology
Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF) in-vitro and in-vivo assay systems. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab has an approximate molecular weight of 149 kD. Bevacizumab is produced in a mammalian cell (Chinese Hamster Ovary) expression system in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. Bevacizumab is a clear to slightly opalescent, colorless to pale brown, sterile, pH 6.2 solution for intravenous infusion.
Dosage & Administration
Patients should continue treatment until disease progression or unacceptable toxicity.
Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.
Administer 5 mg/kg when used in combination with bolus-IFL.
Administer 10 mg/kg when used in combination with FOLFOX4.
Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.
Non-Squamous Non-Small Cell Lung Cancer: (NSNSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.
Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.
Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.
Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.
Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).
Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: The recommended dose is 15 mg/kg every 3 weeks when administered in combination with carboplatin and paclitaxel for 6 cycles and up to 8 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until disease progression. Alternatively, 15 mg/kg every 3 weeks when administrated in combination with carboplatin and gemcitabine for 6 cycles and up to 10 cycles, followed by continued use of Bevacizumab 15 mg/kg every 3 weeks as a single agent until disease progression.
Interaction
A drug interaction study was performed in which irinotecan was administered as part of the FOLFIRI regimen with or without Abevmy. The results demonstrated no significant effect of Abevmy on the pharmacokinetics of irinotecan or its active metabolite SN38.
Contraindications
There are no contraindications listed in the manufacturer’s labeling.
Side Effects
Most common adverse reactions (incidence >10% and at least twice the control arm rate) are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, rectal hemorrhage, lacrimation disorder, back pain and exfoliative dermatitis.
Pregnancy & Lactation
Pregnancy: Bevacizumab may cause fetal harm based on findings from animal studies and the drug’s mechanism of action.
Lactation: No data are available regarding the presence of bevacizumab in human milk, the effects on the breast fed infant, or the effects on milk production. Human IgG is present in human milk, but published data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts. Because of the potential for serious adverse reactions in breastfed infants from bevacizumab, advise a nursing woman that breastfeeding is not recommended during treatment with Bevacizumab.
Precautions & Warnings
Perforation or Fistula: Discontinue Abevmy if perforation or fistula occurs.
Arterial Thromboembolic Events or ATE (e.g., myocardial infarction, cerebral infarction): Discontinue Abevmy for severe ATE.
Venous Thromboembolic Events or VTE: Discontinue Abevmy for lifethreatening VTE.
Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Abevmy if not medically controlled. Discontinue Abevmy for hypertensive crisis or hypertensive encephalopathy.
Proteinuria: Monitor urine protein. Discontinue Abevmy for nephrotic syndrome. Temporarily suspend Abevmy for moderate proteinuria.
Infusion Reactions: Stop Abevmy for severe infusion reactions.
Embryo-fetal Toxicity: Advise females of potential risk to a fetus and the need for use of effective contraception.
Ovarian Failure: Advise females of the potential risk.
Overdose Effects
The highest dose tested in humans (20 mg/kg IV) was associated with headache in nine out of 16 patients and with severe headache in three out of 16 patients.
Storage Conditions
Store the Abevmy vial in a refrigerator at 2-8°C. Keep the vial in the outer carton due to light sensitivity. Do not freeze. Keep out of reach of children.
Alternative brands of Bevacizumab
Other brands with the same generic name, cheapest first.